Boehringer Ingelheim’s Pradaxa Will Garner Blockbuster Sales of $1.3 Billion by 2018 in the Atrial Fibrillation Drug Market

Positive Results From the RE-LY Clinical Trial Will Help Drive Pradaxa's Uptake, According to New Findings from Decision Resources WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Pradaxa will become one of the leading stroke prevention therapies in the atrial fibrillation drug market, garnering blockbuster sales of $1.3 billion by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Read the full article at Health